Effect of angiotensin-converting enzyme inhibitor YS980 on prostaglandin synthesis in rabbit kidney medulla slices. 1987

Y Fujimoto, and K Wada, and M Kaneko, and T Fujita
Department of Hygienic Chemistry, Osaka University of Pharmaceutical Sciences, Japan.

The effect of YS980, an angiotensin-converting enzyme inhibitor, on the generation of medullary prostaglandins E2 and F2 alpha was examined. At concentrations of 0.2 mM and below, YS980 enhanced prostaglandin F2 alpha synthesis at the expense of prostaglandin E2. At concentrations of 0.4 mM or more, YS980 inhibited synthesis of both prostaglandins E2 and F2 alpha markedly. These results suggest that YS980 has the potential to modulate prostaglandins E2 and F2 alpha synthesis by the kidney and that this effect may represent some pharmacological action of the drug.

UI MeSH Term Description Entries
D007679 Kidney Medulla The internal portion of the kidney, consisting of striated conical masses, the renal pyramids, whose bases are adjacent to the cortex and whose apices form prominent papillae projecting into the lumen of the minor calyces. Kidney Papilla,Kidney Medullas,Kidney Papillas,Medulla, Kidney,Medullas, Kidney,Papilla, Kidney,Papillas, Kidney
D008297 Male Males
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D011460 Prostaglandins F (9 alpha,11 alpha,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha)); (5Z,9 alpha,11,alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (PGF(2 alpha)); (5Z,9 alpha,11 alpha,13E,15S,17Z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring PGF have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics. PGF
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001241 Aspirin The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) Acetylsalicylic Acid,2-(Acetyloxy)benzoic Acid,Acetysal,Acylpyrin,Aloxiprimum,Colfarit,Dispril,Easprin,Ecotrin,Endosprin,Magnecyl,Micristin,Polopirin,Polopiryna,Solprin,Solupsan,Zorprin,Acid, Acetylsalicylic
D013438 Sulfhydryl Compounds Compounds containing the -SH radical. Mercaptan,Mercapto Compounds,Sulfhydryl Compound,Thiol,Thiols,Mercaptans,Compound, Sulfhydryl,Compounds, Mercapto,Compounds, Sulfhydryl
D015097 3-Mercaptopropionic Acid An inhibitor of glutamate decarboxylase. It decreases the GAMMA-AMINOBUTYRIC ACID concentration in the brain, thereby causing convulsions. 3-Mercaptopropanoic Acid,beta-Mercaptopropionate,3 Mercaptopropanoic Acid,3 Mercaptopropionic Acid,Acid, 3-Mercaptopropanoic,Acid, 3-Mercaptopropionic,beta Mercaptopropionate

Related Publications

Y Fujimoto, and K Wada, and M Kaneko, and T Fujita
April 1987, The Journal of pharmacy and pharmacology,
Y Fujimoto, and K Wada, and M Kaneko, and T Fujita
October 1986, Research communications in chemical pathology and pharmacology,
Y Fujimoto, and K Wada, and M Kaneko, and T Fujita
December 1985, The Biochemical journal,
Y Fujimoto, and K Wada, and M Kaneko, and T Fujita
December 1982, Experientia,
Y Fujimoto, and K Wada, and M Kaneko, and T Fujita
January 1982, Biochimica et biophysica acta,
Y Fujimoto, and K Wada, and M Kaneko, and T Fujita
February 1985, The Journal of pharmacy and pharmacology,
Y Fujimoto, and K Wada, and M Kaneko, and T Fujita
March 1984, The Journal of pharmacy and pharmacology,
Y Fujimoto, and K Wada, and M Kaneko, and T Fujita
January 1986, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology,
Y Fujimoto, and K Wada, and M Kaneko, and T Fujita
April 1983, The Biochemical journal,
Y Fujimoto, and K Wada, and M Kaneko, and T Fujita
March 1987, The Journal of pharmacy and pharmacology,
Copied contents to your clipboard!